BioLoomics develops monoclonal antibodies for targeted cancer therapies using specialized bioprocessing techniques to enhance therapeutic efficacy and specificity. The company provides treatment options that improve patient outcomes while minimizing adverse side effects in oncology.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) face limitations in payload delivery to cancer cells, hindering their efficacy and potentially leading to off-target toxicity. Existing ADCs may not efficiently internalize into cells or traffic to the appropriate subcellular compartments for optimal drug release.
Solution
BioLoomics is developing a novel approach to antibody-drug conjugates (ADCs) by engineering antibodies with peptides that enhance payload delivery. Their technology leverages directed evolution to create antibody-peptide chimeras that improve internalization and trafficking of ADCs to specific subcellular organelles. By optimizing membrane loading, internalization, and target-specific cytotoxicity, BioLoomics aims to create safer and more effective cancer therapeutics. The company's approach combines synthetic biology, artificial intelligence, imaging, and robotics to screen and optimize antibody libraries. This platform enables the discovery of ADCs with enhanced payload delivery and improved therapeutic outcomes.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing advanced cancer therapies, specifically antibody-drug conjugates.
Features
- Directed evolution platform for engineering antibodies with enhanced internalization and trafficking properties
- Proprietary technology to discover antibody-peptide chimeras that traffic to specific subcellular organelles
- Activity-guided antibody library screening using synthetic biology, AI, imaging, and robotics
- High-throughput wet-lab process for testing millions of peptide designs
- Optimization of ADCs for membrane loading and target-specific cytotoxicity
- Capability to generate best-in-class therapeutics against clinically validated oncology targets